A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis

Puneeta Tandon1, K Rajender Reddy2, Jacqueline G O'Leary3

  • 1University of Alberta, Edmonton, AB, Canada.

Insights

A new Karnofsky Performance Status (KPS) score helps identify cirrhosis patients at high risk of 3-month mortality after hospital discharge, guiding early interventions and palliative care strategies.

Area of Science:

  • Hepatology
  • Clinical Prognostics
  • Patient Outcomes

Background:

  • Identifying cirrhosis patients at high risk for 3-month postdischarge mortality is crucial for tailoring care plans.
  • The Karnofsky Performance Status (KPS) is a potential tool for risk stratification in these patients.

Purpose of the Study:

  • To develop and validate an accessible prognostic model for predicting 3-month mortality in cirrhosis patients using KPS.
  • To compare the predictive accuracy of a KPS-based model against existing models like the Model for End-Stage Liver Disease (MELD).

Main Methods:

  • Prospective enrollment of 954 cirrhosis patients across 16 hepatology centers.
  • KPS assessment at one week postdischarge, categorized into low, intermediate, and high performance groups.
  • Development of a prognostic model incorporating KPS, age, and MELD score to predict 3-month mortality.

Main Results:

  • Mortality rates were significantly higher in the low KPS group (23%) compared to intermediate (11%) and high (5%) groups.
  • Low KPS was associated with older age, dialysis, hepatic encephalopathy, longer hospital stay, and higher MELD scores.
  • The KPS-based model demonstrated superior discrimination (AUC=0.74) compared to MELD alone (AUC=0.62) or MELD and age (AUC=0.67).

Conclusions:

  • A novel KPS-based prognostic score effectively identifies cirrhosis patients at risk for 3-month postdischarge mortality.
  • This KPS score can guide the implementation of early interventions, including palliative care, for high-risk patients.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
309
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
247
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
709
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
320
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
276